Syngene International Ltd reported a strong performance in Q4FY25 with revenue from operations rising 11% year-on-year to ₹1,018 crore, marking the first time the company has crossed the ₹1,000 crore threshold in a single quarter. Operating EBITDA rose 9% year-on-year to ₹363 crore, while profit after tax stood at ₹183 crore.
For the full financial year FY25, revenue from operations grew 4% to ₹3,642 crore, with operating EBITDA increasing by 3% to ₹1,114 crore. However, profit after tax before exceptional items declined 8% to ₹475 crore. Adjusted for one-time items, PAT saw a marginal increase of 1% YoY. The Board has recommended a final dividend of ₹1.25 per share, subject to shareholder approval.
Q4FY25 Key Metrics:
-
Revenue from operations: ₹1,018 Cr (↑11% YoY)
-
EBITDA: ₹363 Cr (↑9% YoY), margin at 34%
-
PAT: ₹183 Cr (↓3% YoY)
FY25 Key Metrics:
-
Revenue from operations: ₹3,642 Cr (↑4% YoY)
-
EBITDA: ₹1,114 Cr (↑3% YoY), margin at 29%
-
PAT: ₹475 Cr (↓8% YoY)
Strategic Highlights:
-
Acquisition of a biologics manufacturing facility in Baltimore, USA, boosting Syngene’s single-use bioreactor capacity to 50,000L.
-
Strong growth in the biologics CDMO segment, supported by commercial manufacturing and new development projects.
-
Continued investment in research automation, including SYNe-MAP™, a new B2B e-commerce platform.
-
Emissions reduction targets validated by Science Based Targets initiative (SBTi).
Management Commentary: Peter Bains, Managing Director and CEO, said, “We’ve ended the year on a high with double-digit growth in Q4 and robust performance in our biologics and discovery services. While challenges remain in the external market, our order book and client pipeline position us well for early-teens revenue growth in FY26.”
CFO Deepak Jain added, “Despite headwinds, we improved our net cash position and maintained strong margins. With capacity expansion in place, we expect EBITDA margin to moderate slightly in FY26 due to increased depreciation and costs from the new US facility.”
Outlook: Syngene expects mid-single-digit revenue growth in FY26, with margin moderation to the mid-twenties range. Long-term growth is expected to be driven by its integrated CRDMO model across research, development, and manufacturing.
